This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
The Dow Jones uses price weighting, which gives more influence to higher-priced stocks. This note covers the rationale and implications for investors.
25,369 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Six Dividend Aristocrats inside SCHD provide ballast for the fund as markets remain volatile. Here’s who leads the in...
Strive disclosed a marked drop in fair value for Strategy’s STRC, signaling a bitcoin treasury’s paper loss that coul...
Banks are rethinking loan terms as data centers emerge real, creating a split in housing markets: regional value gain...
GPIQ carries the lowest fee in the Nasdaq-100 income ETF group, at 0.29%, intensifying the debate over cost versus yi...
As QYLD pays a steady monthly yield, investors may face a hidden wealth drag from capped upside and return-of-capital...
D.R. Horton posted stronger third-quarter profitability but trimmed its full-year guidance, signaling a pivot to marg...
Micron Technology finished a powerful year in 2026, with profits surging as AI infrastructure needs grew. This guide ...
Bitcoin surged on news of a delay in Iran strikes, signaling relief in a tense market. Oil and gold retraced losses a...
Bitcoin shows a bullish weekly signal as a MACD cross fuels renewed upside bets. The coin sits around $84,000 with tr...
Bitcoin stays above $81,000 as geopolitical strains involving Iran collide with crypto flows. A $1 billion ETH unwind...
KeyBanc raises NVIDIA's price target to $300 ahead of May earnings, pointing to Blackwell and Rubin as near-term cata...